Insurers support lower drug prices for Canadians
Right now, Canadians pay some of the highest prices for prescription drugs in the world.
Changes that are ready to go into effect on January 1, 2021 will protect Canadians from excessive drug pricing. Improvements to Canada’s patented drug pricing regulations will lower drug costs by excluding high cost nations – like the United States - from how drug prices are set in Canada.
Canada’s life and health insurers support these improvements to the Patented Medicines Regulations and are ready to do our part. Through workplace benefit plans, insurers provide employers and their employees with access to over 11,000 patented medicines – 41% more than even the most generous provincial plan. Lower drug costs will help to keep these plans sustainable.
News Release
CLHIA welcomes final guidelines to keep prescription medications affordableRelease Date: 10/23/2020
Backgrounder
Patented medicine pricing reforms will lower drug costs for all CanadiansRelease Date: 08/25/2020
Submissions
Submission to the Patented Medicine Prices Review Board on the proposed draft guidelines
Release Date: 08/05/2020
CLHIA provides comments on PMPRB’s consultation on the proposed draft guidelines to support implementation of the amendments made to the Patented Medicines Regulations which will come into force January 1, 2021.
Letter to the Prime Minister in support of the amendments to Patented Medicines Regulations
Release Date: 03/03/2020
CLHIA enforces its strong support for the proposed draft guidelines to support implementation of the amendments made to the Patented Medicines Regulations which will come into force July 1, 2020.
Patented Medicine Prices Review Board Regulations (PMPRB) Consultation on Draft Guidelines Submission
Release Date: 02/14/2020
Submission on PMPRB’s consultation on the proposed draft guidelines to support implementation of the amendments made to the Patented Medicines Regulations which will come into force July 1, 2020. In our view, the proposed changes strike the right balance between reducing the high cost of prescription drugs in Canada, while also continuing to ensure Canadians have access to affordable and necessary medications.
